<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20221022056266N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-12-26</date_registration>
      <primary_sponsor>Zanjan University of Medical Sciences</primary_sponsor>
      <public_title>The effect of Oxytocin with Zinc supplement in treating  opiates addiction and improving fertility in Men</public_title>
      <acronym></acronym>
      <scientific_title>Evaluating the effect of Oxytocin with Zinc sulphate on the withdrawal symptoms, craving, anxiety and reproductive indices in opiates addicted men under Methadone Maintenance Therapy</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-01-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>40</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/66785</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: First, using the Random number generation plugin in Excel software, a table of random numbers from 1 to 40 is prepared in a non-sequential and scattered manner, and intervention and control are done by assigning numbers to two groups of 20 people. The randomization process is done by the study consultant, and the clinical researchers do not know about the randomization process, and only randomized codes from 1 to 40 will be provided to them, Blinding description: After selecting the samples, none of the sampled people will know about randomization and the process of allocation to groups. Researchers are given a table of coded numbers in advance, and patients are included in the study in the order of the numbers in the table. Therefore, the present study is double-blind. Oxytocin spray, zinc sulfate capsule, and placebo are both identical in shape, color, and size, and are delivered to the patient in a package.</study_design>
      <phase>3</phase>
      <hc_freetext>Dependence on opioids.</hc_freetext>
      <i_freetext>Intervention 1: Control group: A sample of 20 people will be the control group, who will receive oxytocin spray placebo and zinc sulfate placebo for fourteen days. Intervention 2: Intervention group: A sample of twenty people will be the intervention group, who will receive oxytocin nasal spray and zinc sulfate capsules for fourteen days.The intervention group will receive 40 international units of oxytocin nasal spray and one 220 mg zinc sulfate capsule daily.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The data should be such that they do not need additional explanation

When:
Access starts six months after results are published

To whom:
The data will be available only to researchers working in academic and scientific institutions.

Conditions:
It will be available to researchers in academic and scientific institutions for the purpose of research development.

Where to obtain:
A journal that works in the field of addiction and will accept the publication of research articles

How to obtain:
According to the rules of the  journal

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Ehsan Sabouri</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Dr. Beheshti Hospital, Arg Square, Zanjan</address>
        <city>Zanjan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۴۵۱۳۶۱۵۸۷۷</zip>
        <telephone>+98 24 3354 4001</telephone>
        <email>saboory@zums.ac.ir</email>
        <affiliation>Zanjan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Ehsan Sabouri</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Dr. Beheshti Hospital, Arg Square, Zanjan</address>
        <city>Zanjan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۴۵۱۳۶۱۵۸۷۷</zip>
        <telephone>+98 24 3354 4001</telephone>
        <email>saboory@zums.ac.ir</email>
        <affiliation>Zanjan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>According to the DSM-5, a person must qualify for opioid dependence
The patient is being treated with methadone maintenance and is stabilized on it
The patient must give written consent to participate in the intervention
People participating in the intervention must be male and between 20 and 50 years old and must be literate</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>50 years</agemax>
      <gender>Male</gender>
      <exclusion_criteria>Having suicidal thoughts
History of any kind of blood disease, glandular disease, heart disease, lung disease, kidney disease, drug sensitivity, diabetes
People with major depressive disorder
People receiving glucocorticoid treatment in the last month
People receiving serotonergic therapy or other antidepressants</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>F00–F99</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>withdrawal symptoms, Craving, Anxiety, Opiate Addicted men, Fertility</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Placebo</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Control group: A sample of 20 people will be the control group, who will receive oxytocin spray placebo and zinc sulfate placebo for fourteen days.</i_keyword>
      <i_keyword>Intervention group: A sample of twenty people will be the intervention group, who will receive oxytocin nasal spray and zinc sulfate capsules for fourteen days.The intervention group will receive 40 international units of oxytocin nasal spray and one 220 mg zinc sulfate capsule daily.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Oxytocin. Timepoint: Before and after the intervention and two months later for follow-up. Method of measurement: Hormonology.</prim_outcome>
      <prim_outcome>Zinc. Timepoint: Before and after the intervention and two months later for follow-up. Method of measurement: Measurement of zinc level in blood.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Clinical Opiate Withdrawal Scale. Timepoint: Before and after the intervention and two months later for follow-up. Method of measurement: Through the checklist for withdrawal symptoms:For each item, circle the number that best describes the patient' s signs or symptom.</sec_outcome>
      <sec_outcome>Craving. Timepoint: Before and after the intervention and two months later for follow-up. Method of measurement: Desire for Drug Questionnaire.</sec_outcome>
      <sec_outcome>Stress. Timepoint: Before and after the intervention and two months later for follow-up. Method of measurement: Depression- Anxiety- Stress Scale.</sec_outcome>
      <sec_outcome>Anxiety. Timepoint: Before and after the intervention and two months later for follow-up. Method of measurement: Depression- Anxiety- Stress Scale.</sec_outcome>
      <sec_outcome>Depression. Timepoint: Before and after the intervention and two months later for follow-up. Method of measurement: Depression- Anxiety- Stress Scale.</sec_outcome>
      <sec_outcome>Testosterone. Timepoint: Before and after the intervention and two months later for follow-up. Method of measurement: Hormonology.</sec_outcome>
      <sec_outcome>Spermogram. Timepoint: Before and after the intervention and two months later for follow-up. Method of measurement: In the Spermogram, two characteristics of semen are considered: 1- Macroscopic characteristics 2- Microscopic characteristics Macroscopic characteristics of semen including color, transparency, concentration of hydrogen ions or pH, volume, duration of closeness, fluidity and viscosity are examined. take The microscopic characteristics of semen include motility, sperm count, viability, sperm morphology, white and red blood cells, and the quality of fructose levels in semen.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Zanjan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-06-21</approval_date>
        <contact_name>Ethics committee of Zanjan University of Medical Sciences</contact_name>
        <contact_address>Zanjan University of Medical Sciences , Azadi Square, Zanjan, Iran Zanjan Zanjan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
